Navigation Links
Agendia Signs Contract with Blue Shield of California
Date:1/5/2012

gendia's Symphony™ suite of breast cancer products is based on the analysis of hundreds of genes in a patient's breast and provides unprecedented biological insight to address complex treatment decisions. Symphony includes MammaPrint, the first and only FDA-cleared IVDMIA breast cancer recurrence assay, as well as BluePrint­­, a molecular subtyping assay, TargetPrint®, an ER/PR/HER2 expression assay, and TheraPrint®, a therapy selection assay. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo or hormonal therapy, and which patients do not require these treatments and can instead be treated with other less arduous and costly methods.

In addition to the Symphony suite of tests, Agendia has a rich pipeline of genomic products in development based on its world-class genomic platform. The company also collaborates with pharmaceutical companies to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and MINDACT trials.

Agendia was founded in 2003 as a spin-off of the Netherlands Cancer Institute and is based in Irvine, California, United States, and Amsterdam, the Netherlands. For more information, please visit www.agendia.com.

For further information, please contact:

Ricochet Public Relations
Todd Aydelotte
Tel: +1 212 679 3300
E-mail: todd@ricochetpr.com


'/>"/>
SOURCE Agendia
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Agendia to Present Five Abstracts at 2011 San Antonio Breast Cancer Symposium
2. EORTC, BIG, and Agendia Announce Completion of Patient Recruitment for International MINDACT Study
3. Agendia Successfully Completes Bi-Annual FDA Inspection
4. Agendia Presents Broad Array of Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO 2010 Annual Meeting
5. Agendia Receives New York State Laboratory Permit and Laboratory Accreditation by College of American Pathologists
6. Medicare Administrator Establishes Reimbursement Coding Policy for Agendias Breast Cancer Recurrence Test MammaPrint(R)
7. Agendia Raises US $23 Million in Series E Financing
8. Agendia Supports Genentechs Citizens Petition Urging FDA to Hold In-Vitro Diagnostic Tests to One Set of Scientific and Regulatory Standards
9. Agendia Opens CLIA-Registered U.S. Genomics Laboratory
10. Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting
11. Agendia to Present at BioCenturys Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... 1, 2015  Adaptive Biotechnologies today announced publication ... Lancet Oncology showing that analysis of circulating ... minimal residual disease (MRD) detection and quantification technology ... identifies patients with diffuse large B-cell lymphoma (DLBCL) ... treatment, usually several months before disease can be ...
(Date:4/1/2015)... April 1, 2015  VLP Therapeutics, LLC. ("VLP"), a ... the research and development of therapeutic and preventative vaccines ... and proprietary vaccine technology, today announced that it has entered ... Medicine at Nagasaki University in ... VLP,s research and development of dengue vaccine candidates. ...
(Date:4/1/2015)... Proove Biosciences , a commercial ... two scientific posters at the Annual Clinical Genetics Meeting ... event was hosted at the Salt Palace Convention Center ... genetic and genomic professionals on breakthrough advances in clinical ... on the Role of DAT1 in Risk of Insomnia ...
(Date:4/1/2015)... 30, 2015 Research and Markets ... the "Forensic Technologies and Services - Global ... This report analyzes the US market ... by the following Segments: Forensic Databases, Forensic Consulting ... Annual estimates and forecasts are provided ...
Breaking Biology Technology:Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 2Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 3Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 4Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 5VLP Therapeutics Enters Collaboration with Institute of Tropical Medicine, Nagasaki University 2VLP Therapeutics Enters Collaboration with Institute of Tropical Medicine, Nagasaki University 3Proove Biosciences Presents Research Studies at Annual Clinical Genetics Meeting 2015 2Forensic Technologies and Services - Global Strategic Business Report 2015-2020: Rise in Terrorist Bombings Sharpens the Business Case for Explosives Forensics 2Forensic Technologies and Services - Global Strategic Business Report 2015-2020: Rise in Terrorist Bombings Sharpens the Business Case for Explosives Forensics 3Forensic Technologies and Services - Global Strategic Business Report 2015-2020: Rise in Terrorist Bombings Sharpens the Business Case for Explosives Forensics 4Forensic Technologies and Services - Global Strategic Business Report 2015-2020: Rise in Terrorist Bombings Sharpens the Business Case for Explosives Forensics 5Forensic Technologies and Services - Global Strategic Business Report 2015-2020: Rise in Terrorist Bombings Sharpens the Business Case for Explosives Forensics 6Forensic Technologies and Services - Global Strategic Business Report 2015-2020: Rise in Terrorist Bombings Sharpens the Business Case for Explosives Forensics 7
... of our nation,s long-term clean-energy future, but the technology ... Japan,s recent Fukushima disaster. Indeed, many nations have called ... are operating safely. In the United States, ... percent of the electricity from emission-free sources, including renewable ...
... Mediabrands, IPG Media Lab and Affectiva today announced, ... results of the first annual Neuromarketing Awards. Utilizing ... record and measure viewers, tacit, non-verbal response to ... features are established and are then measured and ...
... ,   The randomised, ... efficacy and safety of,the monoclonal antibody rituximab (RTX) ... that in patients with,severe AAV a single course ... period of 18 months proved to be as ...
Cached Biology Technology:Berkeley scientists pioneer nanoscale nuclear materials testing capability 2The IPG Media Lab and Affectiva Announce Winners of First Annual Neuromarketing Awards 2The IPG Media Lab and Affectiva Announce Winners of First Annual Neuromarketing Awards 3ERA-EDTA Congress 2011: Late Breaking Clinical Trials I 2
(Date:3/30/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has ... Market in Automotive Sector 2014-2018" report to their ... Recognition market in Automotive Sector to grow at a ... Gesture recognition is the ability of a device to ... Gesture recognition technology can be 2D-based or 3D-based. It ...
(Date:3/24/2015)... 24, 2015   NexID Biometrics LLC, whose ... needs, today announced the beginning of shipments of version ... The company, based in Potsdam, N.Y. ... Connect:ID Expo, which began here today at the Walter ... 2.0 of its SDK boosts the accuracy rate range ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... closely associated with the African savanna -- fierce lions, ... players when it comes to shaping the ecosystem. ... be the termite, say ecologists who,ve found that these ... Kenya via a network of uniformly distributed colonies. Termite ...
... study finds heterotrophic bacteria counts, in more than 70 ... specified by the United States Pharmacopeia (USP). Researchers ... 110th General Meeting of the American Society for Microbiology ... water a large number of urban Canadians are switching ...
... animals most closely associated with the African savanna -- ... relatively minor players when it comes to shaping the ... to be the termite, say ecologists who,ve found that ... central Kenya via a network of uniformly distributed colonies. ...
Cached Biology News:The star of Africa's savanna ecosystems may be the lowly termite 2The star of Africa's savanna ecosystems may be the lowly termite 3Study finds high level of bacteria in bottled water in Canada 2Lowly termite, not the lion or elephant, may be the star of Africa's savanna 2Lowly termite, not the lion or elephant, may be the star of Africa's savanna 3
Propidium Iodide: {3,8-diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium diodide}. Antifade Solution: p-Phenylenediamine and glycerol in PBS solution. 2.5ug/mL Propidium Iodide (PI)...
Detects activated caspases in living cells. Simple/sensitive/straight-forward procedure takes only 30 minutes. Results can be analyzed by flow cytometry/fluorescence microscopy/fluorescence plate rea...
Apoptosis Detection Systems and Reagents...
... feeding tubes for rodent oral gavage feature ... of perforation and trauma. Plus they are ... and the risk of cross-contamination. ... 20ga Length: ...
Biology Products: